111 Capital’s AstraZeneca AZN Stock Holding History

111 Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.1M	Buy	112,973 +19,437	+21%	+$3.66M	3.63%	3
2026 Q1	$18.2M	Buy	93,536 +90,906	+3,457%	+$17.5M	4.48%	3
2025 Q4	$483K	Buy	2,630 +262	+11%	+$46K	0.11%	162
2025 Q3	$363K	Buy	2,368 +47	+2%	+$7.11K	0.07%	274
2025 Q2	$324K	Buy	2,321 +45	+2%	+$6.31K	0.06%	340
2025 Q1	$334K	Sell	2,276 -6	-0.3%	-$868	0.06%	296
2024 Q4	$299K	Buy	+2,282	New	+$319K	0.06%	299

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

111 Capital's AZN Position: Q2 2026 in Review

111 Capital increased its AstraZeneca (AZN) stake by 21% in Q2 2026, buying an estimated $3.66M and bringing the position to 112,973 shares worth $21.1M. The position accounts for 3.63% of the portfolio, ranked #3.

111 Capital first reported a position in AZN in Q4 2024 and has held it in 7 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

111 Capital held 112,973 shares of AstraZeneca worth $21.1M as of Q2 2026.
111 Capital bought 19,437 AstraZeneca shares in Q2 2026, an estimated $3.66M.
AstraZeneca made up 3.63% of 111 Capital's portfolio in Q2 2026, its #3 holding.
111 Capital first reported a position in AstraZeneca in Q4 2024 and has held it in 7 quarters since.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on 111 Capital's 13F filing for Q2 2026, filed 5 Aug 2026.